Table 1.

Antiviral activity of MEDS433 against representative influenza viruses.

IV	Cell Line	EC50 (μM) a	EC90 (μM) b	CC50 (μM) c	SI d
IAV	A549	0.064 ± 0.01 μM	0.264 ± 0.002 μM	64.25 ± 3.12 μΜ	1104
	Calu-3	0.055 ± 0.003 μΜ	0.675 ± 0.05 μΜ	54.67 ± 3.86 μΜ	994
	MDCK	0.141 ± 0.021 μM	0.256 ± 0.052 μΜ	119.8 ± 6.21 μΜ	850
IBV	A549	0.065 ± 0.005 μΜ	0.365 ± 0.09 μΜ	64.25 ± 3.12 μΜ	988
	Calu-3	0.052 ± 0.006 μΜ	0.807 ± 0.08 μΜ	54.67 ± 3.86 μΜ	1051
	MDCK	0.170 ± 0.019 μM	0.330 ± 0.013 μΜ	119.8 ± 6.21 μΜ	705

^a EC₅₀, compound concentration that inhibits 50% of replication, as determined by the VRAs in A549 and Calu-3 cells, or by the PRAs in MDCK cells. ^b EC₉₀, compound concentration that inhibits 90% of viral replication. ^c CC₅₀, compound concentration that produces 50% cytotoxicity, as determined by the cell viability assays in A549, Calu-3, or MDCK cells. Reported values represent the means ± SDs of data derived from three experiments in triplicate. ^d SI, selectivity index (determined as the ratio between CC₅₀ and EC₅₀).